SCALING NEW HEIGHTS IN CELL AND GENE THERAPY
7:45am – 8:45am | ARM Ballroom
Sponsored by ZS
In order to overcome the challenges currently facing cell and gene therapies (C>), the next generation of manufacturers must prepare to serve small and large patient populations across a wide range of care settings to harmonize clinical workflows, reduce HCP burden and deliver therapies at a fraction of the current cost. This cannot be achieved by incrementally tweaking the existing model. Rather, it requires leapfrogging the current C> 1.0 “proof-of-concept” to deliver fundamentally new capabilities. To deliver on the promise of C> 2.0, a new approach is required, one that considers the needs more holistically across the end-to-end patient journey.
Chair:
Bill Coyle, Principal, Global Head of BioPharma Vertical, ZS
Speakers:
Taby Ahsan, Ph.D., Vice President, Cell and Gene Therapy Operations, City of Hope
Warner Biddle, Senior Vice President, Global Head of Commercial, Kite Pharma
Jonathon DiTroia, Vice President, Strategy, Cell, Gene and Advanced Therapies, McKesson
George Eastwood, Chairman of the Board, Emily Whitehead Foundation
Kristin Yarema, Ph.D., President, Cell Therapy, Poseida Therapeutics